If a study participant is diagnosed with disease recurrence within the trial period of 3 years, either as lung metastases, liver metastases, or local recurrence in the abdomen, the ASAC trial centre will be informed promptly and the study medications will be discontinued. The participant will however be treated according to the National Guidelines. We will follow-up all participants for the whole study period (3 years) with registration of QoL.